Deka Biosciences has secured funding of $20m in a Series B2 financing round to advance its product pipeline.

MPM BioImpact led the funding round with investors including Leaps by Bayer, Lumira Ventures and O-Bio.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

MPM-BioImpact’s Detlev Biniszkiewicz will now join Deka’s board.

Deka will advance the clinical trials of its DK210 (EGFR), subject to approval from the US Food and Drug Administration (FDA) for the company’s investigational new drug (IND) application. 

Deka CEO John Mumm stated: “We have only raised $55m to date and are already proceeding to dose our third cohort in our Phase I clinical trial. 

“Thus far, we have established safety and clear signs of immune activation in our first two cohorts. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We are encouraged by these results and believe that this combined approach will result in safer, more efficacious and cost-effective immunotherapies.”

The company had previously raised $5m and $20m in seed and Series A financing rounds, respectively.

In 2022, these funds enabled Deka to secure a further $21.5m in its Series B1 funding round, jointly led by Lumira and Leaps by Bayer, and make significant advances.

The company also produced drug products in collaboration with Cytovance Biologics, commenced a Phase I trial and expanded operations into a new plant using these proceeds.

It now intends to progress its development of diakines [disease-targeting scaffolds] and carry out activities that enable the IND filing.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now